药物性肝损伤组学生物标志物新进展

New progress in omics biomarkers of drug-induced liver injury

药物性肝损伤(drug-induced liver injury, DILI)是引起药物不良反应和药物停产或药物撤市的主要原因。临床前药物肝毒性评价和临床患者DILI诊断主要依赖于生物标志物的检测。随着组学技术的发展,人们发现了一些具有更高特异性和敏感性的新型DILI生物标志物。基于蛋白质组学、转录组学、基因组学和代谢组学的新型生物标志物可为临床前药物潜在肝毒性的评价和临床DILI的预测、早期诊断提供参考和依据。

Drug-induced liver injury (DILI) is the main cause of adverse drug reactions and drug discontinuation or withdrawal. Preclinical drug hepatotoxicty evaluation and clinical diagnosis of DILI mainly depend on the detection of biomarkers. With the development of omics technology, some new DILI biomarkers with higher specificity and sensitivity have been found. New biomarkers based on proteomics, transcriptomics,genomics and metabolomics can provide references and bases for the evaluation of potential hepatotoxicity of preclinical drugs, prediction and early diagnosis of clinical DILI.